FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $6,075,724 | -16.9% | 602,153 | +84.5% | 0.19% | -22.2% |
| Q3 2022 | $7,315,000 | +12.2% | 326,419 | +24.0% | 0.24% | +7.2% |
| Q2 2022 | $6,521,000 | -17.9% | 263,156 | +28.4% | 0.22% | +13.2% |
| Q1 2022 | $7,946,000 | +1.8% | 204,945 | +53.6% | 0.20% | +22.4% |
| Q4 2021 | $7,805,000 | +76.8% | 133,401 | +79.1% | 0.16% | +91.7% |
| Q3 2021 | $4,415,000 | – | 74,492 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |